Literature DB >> 17325369

Antibodies specific to the HA2 glycopolypeptide of influenza A virus haemagglutinin with fusion-inhibition activity contribute to the protection of mice against lethal infection.

M Gocník1, T Fislová, T Sládková, V Mucha, F Kostolanský, E Varecková.   

Abstract

Four monoclonal antibodies (mAbs) recognizing distinct antigenic sites on the HA2 glycopolypeptide of influenza virus A/Dunedin/4/73 (H3N2) have been tested for in vivo protection. When applied intravenously before infection, three of them increased the survival of BALB/c mice infected with 1 LD50 homologous virus. The protection resulted simultaneously in 2 days earlier clearance of virus from the lungs. These three antibodies inhibited the fusion activity of virus in previous in vitro experiments. One of them, specific to N-terminal aa 1-38 of the HA2 glycopolypeptide, was also tested for protection against the heterologous virus A/Mississippi/1/85 (H3N2). Protection similar to that against the homologous virus was observed. The fourth mAb, without fusion-inhibition activity, did not protect mice. It is concluded that antibodies specific to the antigenically conserved HA2 glycopolypeptide that exhibit fusion-inhibition activity can contribute to the protection of infected mice and mediate more effective recovery from infection.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17325369     DOI: 10.1099/vir.0.82563-0

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  21 in total

1.  Epitope specificity of anti-HA2 antibodies induced in humans during influenza infection.

Authors:  Zuzana Staneková; Vojtech Mucha; Tatiana Sládková; Hana Blaškovičová; František Kostolanský; Eva Varečková
Journal:  Influenza Other Respir Viruses       Date:  2012-01-12       Impact factor: 4.380

2.  DNA-epitope vaccine provided efficient protection to mice against lethal dose of influenza A virus H1N1.

Authors:  Huiling Wei; Stephen D Lenz; David H Thompson; Roman M Pogranichniy
Journal:  Viral Immunol       Date:  2014-01-09       Impact factor: 2.257

3.  Cold-adapted pandemic 2009 H1N1 influenza virus live vaccine elicits cross-reactive immune responses against seasonal and H5 influenza A viruses.

Authors:  Yo Han Jang; Young Ho Byun; Yoon Jae Lee; Yun Ha Lee; Kwang-Hee Lee; Baik Lin Seong
Journal:  J Virol       Date:  2012-03-21       Impact factor: 5.103

Review 4.  Passive immune neutralization strategies for prevention and control of influenza A infections.

Authors:  Jianqiang Ye; Hongxia Shao; Daniel R Perez
Journal:  Immunotherapy       Date:  2012-02       Impact factor: 4.196

5.  Monoclonal antibodies against the fusion peptide of hemagglutinin protect mice from lethal influenza A virus H5N1 infection.

Authors:  Nayana Prabhu; Mookkan Prabakaran; Hui-Ting Ho; Sumathy Velumani; Jia Qiang; Michael Goutama; Jimmy Kwang
Journal:  J Virol       Date:  2008-12-24       Impact factor: 5.103

6.  Novel hemagglutinin-based influenza virus inhibitors.

Authors:  Xintian Shen; Xuanxuan Zhang; Shuwen Liu
Journal:  J Thorac Dis       Date:  2013-08       Impact factor: 2.895

7.  The epitope and neutralization mechanism of AVFluIgG01, a broad-reactive human monoclonal antibody against H5N1 influenza virus.

Authors:  Zhiliang Cao; Jiazi Meng; Xingxing Li; Ruiping Wu; Yanxin Huang; Yuxian He
Journal:  PLoS One       Date:  2012-05-25       Impact factor: 3.240

8.  A VLP vaccine induces broad-spectrum cross-protective antibody immunity against H5N1 and H1N1 subtypes of influenza A virus.

Authors:  Chia-Ying Wu; Yi-Chun Yeh; Jia-Tsrong Chan; Yu-Chih Yang; Ji-Rong Yang; Ming-Tsan Liu; Ho-Sheng Wu; Pei-Wen Hsiao
Journal:  PLoS One       Date:  2012-08-07       Impact factor: 3.240

9.  Serological response to the 2009 pandemic influenza A (H1N1) virus for disease diagnosis and estimating the infection rate in Thai population.

Authors:  Hatairat Lerdsamran; Chakrarat Pittayawonganon; Phisanu Pooruk; Anek Mungaomklang; Sopon Iamsirithaworn; Prasert Thongcharoen; Uraiwan Kositanont; Prasert Auewarakul; Kulkanya Chokephaibulkit; Sineenat Oota; Warin Pongkankham; Patummal Silaporn; Supaloek Komolsiri; Pirom Noisumdaeng; Tawee Chotpitayasunondh; Chariya Sangsajja; Witthawat Wiriyarat; Suda Louisirirotchanakul; Pilaipan Puthavathana
Journal:  PLoS One       Date:  2011-01-25       Impact factor: 3.240

Review 10.  Influenza A virus entry inhibitors targeting the hemagglutinin.

Authors:  Jie Yang; Minmin Li; Xintian Shen; Shuwen Liu
Journal:  Viruses       Date:  2013-01-22       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.